Boston, MA -- (SBWIRE) -- 01/24/2013 -- GlobalData has released its new PharmaPoint Drug Evaluation report, Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Pfizer has developed Xeljanz (tofacitinib;formerly known as tasocitinib), an oral, small-molecule inhibitor of JAK3 kinase for the treatment of RA, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, transplant rejection, and dry eye syndrome. Xeljanz (tofacitinib) is the most advanced kinase inhibitor in development for RA and is a first-in-class product. Xeljanz (tofacitinib) targets the JAK pathway, thus disrupting the intracellular signal pathway through which cytokines regulate immune responses.

View Full Report Details and Table of Contents

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Xeljanz (tofacitinib) including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Xeljanz (tofacitinib) for the top eight countries from 2011 to 2022.
- Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia.

Reasons to Get this Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Xeljanz (tofacitinib) performance
- Obtain sales forecast for Xeljanz (tofacitinib) from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Rheumatoid Arthritis - Spain Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - Germany Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - Italy Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - Japan Drug Forecast and Market Analysis Event-Driven Update
- PharmaPoint: Rheumatoid Arthritis - Australia Drug Forecast and Market Analysis Event-Driven Update
- Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Product Profiles: Disease Modification in Rheumatoid Arthritis - Game-changing therapy close to market